European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

NeuroSAFE results show enhanced precision preserves erectile function

According to the NeuroSAFE PROOF trial results presented at EAU25, NeuroSAFE-guided RARP enhances traditional nerve-sparing robotic surgery by incorporating an intraoperative assessment, significantly improving surgical precision for patients with localised prostate cancer. As a result, nearly twice as many men preserve their erectile function compared to those undergoing standard RARP.

Thu, 27 Mar 2025
LUTSFunctional UrologyProstate CancerContinenceErectile DysfunctionEAU 25Annual EAU Congress
Enlarge image

The NeuroSAFE procedure allows surgeons to determine whether preserving the prostate’s outer nerve layers is safe without compromising cancer removal. As Prof. Greg Shaw (GB) explained, “By using NeuroSAFE, nearly twice as many men don’t have to face potentially life-changing loss of erectile function after prostate surgery.” He emphasised that while the procedure requires expertise, it is not costly and does not compromise cancer control.

The trial involved 344 men with prostate cancer who had no prior erectile dysfunction. They were randomly assigned to undergo either NeuroSAFE or standard surgery. One year post-surgery, 39% of NeuroSAFE patients had no or mild erectile dysfunction, compared to just 23% in the standard surgery group. Furthermore, only 38% of NeuroSAFE patients experienced severe erectile dysfunction, compared to 56% in the standard group.

While NeuroSAFE did not significantly improve overall urinary continence rates at 12 months, those who regained control did so more quickly. 

NeuroSAFE has been widely used in Germany for over a decade, but this is the first randomised trial to validate its benefits. Experts believe further trials could confirm its long-term impact on cancer control and post-surgical recovery.

More information

  • Related webcast: NeuroSAFE versus standard robot-assisted radical prostatectomy (NeuroSAFE PROOF): a randomised, controlled, patient-blinded, IDEAL stage 3 trial.
  • Read the press release.

Share this article

Suggested for you

See all
About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer